RAS Inhibition Enters Its Second Wave

Why It Matters

Expanding RAS‑targeted therapies to dominant KRAS mutations opens treatment options for pancreatic cancer and other hard‑to‑treat tumors, reshaping the oncology market and driving substantial R&D investment.

Key Takeaways

• Daraxonrasib showed median OS 13.2 months vs 6.7 months in pancreatic cancer
• KRAS G12C combos approved for colorectal cancer improve PFS to 5.6 months
• New G12D inhibitors and degraders target dominant pancreatic KRAS mutations
• Resistance drives focus on combination regimens and active‑state RAS targeting
• Lilly, Roche, Bayer each advancing next‑gen KRAS inhibitors in trials

Pulse Analysis

The RAS family has long been labeled "undruggable" because its smooth surface offers few binding pockets. Early attempts focused on downstream pathways until covalent KRAS G12C inhibitors—sotorasib and adagrasib—proved that direct targeting was feasible, earning accelerated FDA approvals for non‑small cell lung cancer and later for KRAS G12C‑mutated colorectal cancer. While these agents demonstrated clinical activity, resistance emerged through secondary KRAS mutations and bypass signaling, highlighting the need for broader strategies.

The current "second wave" shifts attention to the mutations that dominate pancreatic ductal adenocarcinoma, chiefly KRAS G12D and G12V. Revolution Medicines’ daraxonrasib, a multi‑selective RAS(ON) inhibitor, achieved a median overall survival of 13.2 months in a pivotal phase‑3 trial, more than doubling the benefit of standard chemotherapy. Complementary programs—zoldonrasib, setidegrasib, and Verastem’s VS‑7375—explore active‑state inhibition, targeted protein degradation, and dual‑state binding, aiming to overcome the biochemical challenges of non‑cysteine mutations.

Resistance remains the central obstacle, prompting a wave of combination studies that pair KRAS inhibitors with EGFR antibodies, immune checkpoint blockers, or chemotherapy. Major players such as Eli Lilly, Roche/Genentech, and Bayer are advancing next‑generation KRAS agents into late‑stage trials, signaling a crowded but promising pipeline. If these candidates deliver durable responses, the market for RAS‑targeted oncology drugs could expand from niche lung indications to the broader, high‑unmet‑need landscape of pancreatic and colorectal cancers, reshaping treatment paradigms and investor expectations.